Gambuzza, Maria Elsa, Salmeri, Francesca Maria, Soraci, Luca et al. · CNS & neurological disorders drug targets · 2015 · DOI
This review examines how certain immune system sensors called Toll-like receptors (TLRs) may contribute to ME/CFS. These receptors sit on cells in the gut and detect bacteria and other microbes, triggering inflammation that may spread to the brain and cause fatigue and other symptoms. The researchers suggest that targeting these TLRs with new medications might help reduce inflammation and improve symptoms.
Understanding the mechanisms driving ME/CFS inflammation is critical for developing effective treatments. This review identifies TLRs as a potential therapeutic target, offering hope for new drug development strategies that could interrupt the inflammatory cascade and provide symptom relief for ME/CFS patients.
This review does not present new experimental data proving that TLR dysfunction causes ME/CFS—it synthesizes existing literature. It does not establish that TLR-targeting drugs will be effective in humans with ME/CFS, nor does it determine causation versus correlation in the gut microbiome-immune-neurological relationships it describes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.